{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:42:07Z","timestamp":1788273727465,"version":"build-2803163510"},"reference-count":50,"publisher":"American Psychiatric Association Publishing","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AJP"],"published-print":{"date-parts":[[2026,9,1]]},"DOI":"10.1176\/appi.ajp.20251233","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:00:19Z","timestamp":1785297619000},"page":"624-635","source":"Crossref","is-referenced-by-count":1,"title":["Determinants of Nonspecific Response to Treatment in Randomized Controlled Trials of Major Depressive Disorder: A Narrative Review"],"prefix":"10.1176","volume":"183","author":[{"given":"Clotilde","family":"Guidetti","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5984-8696","authenticated-orcid":false,"given":"Riccardo","family":"De Giorgi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK."},{"name":"Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK."},{"name":"Department of Experimental Medicine, University of Salento, Lecce, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan T.M.","family":"Huneke","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK."},{"name":"Hampshire and Isle of Wight Healthcare NHS Foundation Trust, Southampton, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"De Crescenzo","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Zippi","sequence":"additional","affiliation":[{"name":"Section of Pharmacology, Department of Healthcare Surveillance and Bioethics, Catholic University Medical School, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome."},{"name":"IQVIA, Clinical Operations, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George I.","family":"Papakostas","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Fava","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"230","reference":[{"key":"e_1_3_2_2_2","volume-title":"Major depressive disorder: developing drugs for treatment: guidance for industry","author":"US Food and Drug Administration (FDA):","year":"2018","unstructured":"US Food and Drug Administration (FDA): Major depressive disorder: developing drugs for treatment: guidance for industry. Silver Spring, MD, FDA, June 2018. https:\/\/www.fda.gov\/media\/113988\/download"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1159\/000069738"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291720003633"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01600-9"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02443-0"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2025.116506"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-019-0585-z"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000669"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.4602"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.2416"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000490354"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2017.10.016"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009655"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510440069036"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3923"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-024-02638-x"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.0085"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2008.08.009"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08r04516blu"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2026.0096"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)00066-1"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079908X291958"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"e067606","DOI":"10.1136\/bmj-2021-067606","article-title":"Response to acute monotherapy for major depressive disorder in randomized, placebo-controlled trials submitted to the US Food and Drug Administration: individual participant data analysis","volume":"378","author":"Stone MB","year":"2022","unstructured":"Stone MB, Yaseen ZS, Miller BJ, et al: Response to acute monotherapy for major depressive disorder in randomized, placebo-controlled trials submitted to the US Food and Drug Administration: individual participant data analysis. BMJ 2022; 378:e067606","journal-title":"BMJ"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.08.006"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181d20912"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(11)72389-6"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.3.628"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.106.032532"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2000.00271.x"},{"key":"e_1_3_2_32_2","volume-title":"Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims","author":"US Food and Drug Administration (FDA)","year":"2009","unstructured":"US Food and Drug Administration (FDA): Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. Silver Spring, MD, FDA, December 2009. https:\/\/www.fda.gov\/media\/77832\/download"},{"key":"e_1_3_2_33_2","volume-title":"Reflection paper on risk based quality management in clinical trials","author":"European Medicines Agency (EMA)","year":"2013","unstructured":"European Medicines Agency (EMA): Reflection paper on risk based quality management in clinical trials. London, EMA, November 18, 2013. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-risk-based-quality-management-clinical-trials-superseded_en.pdf"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000116651.91923.54"},{"key":"e_1_3_2_35_2","first-page":"10","article-title":"Consensus recommendations on rater training and certification","volume":"11","author":"CNS Summit Rater Training and Certification Committee","year":"2014","unstructured":"CNS Summit Rater Training and Certification Committee; West MD, Daniel DG, et al: Consensus recommendations on rater training and certification. Innov Clin Neurosci 2014; 11:10\u201313","journal-title":"Innov Clin Neurosci"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11lr07229"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2021.100713"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1995.tb04469.x"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/da.22045"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1097\/HRP.0b013e3182a75cc7"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881113480990"},{"key":"e_1_3_2_42_2","first-page":"24com15504","article-title":"Functional unblinding in pivotal studies and the future of psychedelic medicine","volume":"85","author":"Rosenbaum JF","year":"2024","unstructured":"Rosenbaum JF: Functional unblinding in pivotal studies and the future of psychedelic medicine. J Clin Psychiatry 2024; 85:24com15504","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2019-111238"},{"key":"e_1_3_2_44_2","unstructured":"Marek G Umbricht D Christian EP et al: Robust antidepressant efficacy of the novel 5-HT2A receptor agonist GM-2505 in a double-blind randomized controlled phase 2a trial in patients with MDD. Poster presented at: American Society of Clinical Psychopharmacology Annual Meeting. May 27\u201330 2025 Scottsdale AZ"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02473-8"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-024-01862-x"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2021.3204"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2016.60"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.0192"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.0206"},{"key":"e_1_3_2_51_2","unstructured":"Spear MA Luo W Chen C et al: Use of a novel pharmacogenomic biomarker to enrich responders to liafensine in treatment resistant depression (TRD) in a phase 2b clinical trial (ENLIGHTEN). Poster presented at: 20th Annual Scientific Meeting of the International Society for CNS Clinical Trials and Methodology. February 21\u201323 2024 Washington DC"}],"container-title":["American Journal of Psychiatry"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:22:56Z","timestamp":1788236576000},"score":1,"resource":{"primary":{"URL":"https:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp.20251233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"alternative-id":["10.1176\/appi.ajp.20251233"],"URL":"https:\/\/doi.org\/10.1176\/appi.ajp.20251233","relation":{},"ISSN":["0002-953X","1535-7228"],"issn-type":[{"value":"0002-953X","type":"print"},{"value":"1535-7228","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}